ID: ALA3104610

Max Phase: Preclinical

Molecular Formula: C22H19N3O2S

Molecular Weight: 389.48

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1nc(-c2cnc(Cc3ccccc3)o2)sc1C(=O)NCc1ccccc1

Standard InChI:  InChI=1S/C22H19N3O2S/c1-15-20(21(26)24-13-17-10-6-3-7-11-17)28-22(25-15)18-14-23-19(27-18)12-16-8-4-2-5-9-16/h2-11,14H,12-13H2,1H3,(H,24,26)

Standard InChI Key:  AYMGVVBGKQTIHD-UHFFFAOYSA-N

Associated Targets(Human)

Fatty acid desaturase 2 102 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Fatty acid desaturase 1 145 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Acyl-CoA desaturase 1011 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Acyl-CoA desaturase 1 352 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 389.48Molecular Weight (Monoisotopic): 389.1198AlogP: 4.63#Rotatable Bonds: 6
Polar Surface Area: 68.02Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.16CX Basic pKa: 0.15CX LogP: 3.54CX LogD: 3.54
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.52Np Likeness Score: -1.66

References

1. Sun S, Zhang Z, Kodumuru V, Pokrovskaia N, Fonarev J, Jia Q, Leung PY, Tran J, Ratkay LG, McLaren DG, Radomski C, Chowdhury S, Fu J, Hubbard B, Winther MD, Dales NA..  (2014)  Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.,  24  (2): [PMID:24374272] [10.1016/j.bmcl.2013.12.036]

Source